16–20 March 2020 — the public submission window closes on a separate agenda item — item 5.3, "Alkyl Nitrites," set down for the Committee's upcoming 64th meeting. This is where the community's actual response landed: a petition carrying over 700 signatures, and individual submissions overwhelmingly opposed — including one from a 62-year-old man, using amyl since 1980, who told the Committee he felt intimidated and deterred from submitting at all, and questioned the legitimacy of the whole process. That window closed fourteen days after the law it was responding to had already taken effect.

The channel the public was being pointed toward could register objection. It could no longer change anything.

12 April 2020 — a member of the public, unconnected to any campaign, files an Official Information Act request asking Medsafe to show the evidence behind the decision. Medsafe's response — public record — says plainly that no information existed answering the Committee's own risk questions, and that feedback from the LGBTQI community was not sought before the classification took effect. A further information paper, it says, is "being prepared."

Late March 2020 onward — national COVID-19 lockdown. The NZ Drug Foundation's own account confirms the Committee's normal follow-up consultation was delayed by lockdown, and the outcome proceeded without the fuller public input that would ordinarily have followed.

9 July 2020 — the 64th meeting, delayed from around May. The Committee reviews the now-substantial public opposition, and notably doesn't defend the classification: it records that it still lacks sufficient information, asks officials to gather more — specifically on black-market development and the real Australian experience — and the Chair undertakes to engage directly with the affected community. 1 September 2020 — Body Positive, the NZ Drug Foundation, the NZ AIDS Foundation and the NZ Sexual Health Society write jointly to Medsafe and the Committee asking them to pause enforcement while a workable access solution is found. Mark Fisher of Body Positive describes the situation publicly as "confusing."

With no approved product ever reaching the New Zealand market, a black market fills the gap — increasingly dominated by isopropyl nitrite. The exact compound the whole exercise should have been most worried about.

22 June 2023 — the Otago research is published, and it deserves a proper walk-through rather than a passing citation, because it's the most substantial independent analysis this whole saga has. Crossin, Whelan, Hughes and Birks Ang, writing in the International Journal of Drug Policy, weren't measuring harm — theirs is a policy analysis, using policy formation theory to examine how the decision actually got made, from a close reading of the real submissions and committee minutes. Their central finding: two camps emerged in the record, framing the same issue in ways that never met. The Committee framed it around the limits of its evidence — essentially, "we don't know enough, so restrict first." The advocacy groups and the guys actually using the product framed it around the absence of any evidence of real-world harm in New Zealand — where there's clear benefit and no local harm, restriction wasn't warranted. The Committee's frame won by default. It never rebutted the other one.

The paper's second finding is structural: the issue arrived on New Zealand's agenda unexpectedly, as a side effect of Australia's process rather than any New Zealand-led inquiry, which — in the authors' words — set it onto "a somewhat pre-determined pathway with limited policy choices available." Plainly: because the decision was reactive rather than considered from first principles, the options genuinely on the table were narrower than a real review would have produced. Everything else follows: the decision was opposed by both users and advocacy groups; limited alternatives were considered; access was significantly reduced; and reduced access likely increased harm for men who have sex with men. At the time the authors gathered their data, they found no availability even through the prescription pathway — a gap two Auckland pharmacies have since partly, narrowly closed.

August 2023 — a Ministry of Health spokesperson says there are no plans to review the classification. In the same reporting, Fisher notes that roughly 50% of gay men in New Zealand aren't out to their doctor at all, and that he personally knows of only three doctors nationally willing to take on the liability of prescribing for import. Some men, he says, are choosing instead to "buy a local product of unknown quality out of a backpack at Big Gay Out."

Now — two Auckland pharmacies, Chemist Plus in Newmarket and Citycare in the CBD, stock a genuine pharmaceutical-grade single-use amyl nitrite ampoule, prescription required, around $10 a vial. Dr Torrance Merkle at Hobsonville Family Doctors remains the only consistently, publicly named doctor willing to sign off on personal import for people without an existing GP relationship — and isn't currently taking new patients.

What's actually wrong with how this was decided

Easiest to follow in the order things break down: the process, then the reasoning, then who it lands on, then what it adds up to.

The process failed on its own terms

The one real round of public consultation closed after the law was already in force. The 63rd meeting's pre-decision consultation drew a single comment — nobody knew to respond. The consultation that actually drew the community's response closed fourteen days after the classification had already taken legal effect. The proper channel was offered to the public at the exact moment it stopped being able to change the outcome.

The Committee admitted, in writing, that it didn't have what it needed — twice — and the deadlines arrived anyway. At the 63rd meeting it deferred the amyl/isopropyl split pending more information; Medsafe's own 2020 response confirms that information never existed. At the 64th meeting, after reviewing overwhelming opposition, it again recorded insufficient information and made undertakings whose fulfilment has never been shown on the public record.

The reasoning doesn't hold up

The classification never distinguishes the one compound that matters. The gazette treats amyl exactly the same as isopropyl, despite the Committee's own recommendation flagging that distinction as still to be made. Australia had already done that work, and published it, four months before New Zealand's Committee even met.

"Harmonise with Australia" doesn't survive contact with what Australia actually did. At the moment of decision, Australia's compound-specific model was public and available to copy — New Zealand chose a blanket line instead. Australia banned isopropyl and n-propyl outright; New Zealand never banned anything, it only required a prescription. And that gap isn't cosmetic: New Zealand's lawful pathway today still lets a doctor prescribe isopropyl nitrite, by name, for personal import — the exact compound Australia prohibits. Whatever this system achieves, it isn't harmonisation with the country cited to justify it.

The eye damage was Australia's reason. It was never New Zealand's. Australia's published decision names retinal maculopathy directly as the basis for banning isopropyl specifically. New Zealand's minutes give harmonisation as the reason for taking the item up, and record the Committee's own uncertainty about the risks. This isn't New Zealand misreading the evidence — it's New Zealand never engaging with it at the point of decision.

And the real numbers are worth having. An earlier review found around 30 published cases of poppers maculopathy worldwide; a 2025 quantitative review found 59, across 19 studies — the count rising as recognition of the condition improves, not because the drug changed. Against decades of widespread international use, that's a real but rare risk, and a specifically isopropyl-linked one.

Who it lands on, and how the access system fails them

The disclosure barrier isn't a footnote — it's close to half the affected population. Roughly 50% of gay men in New Zealand have never told a GP their sexuality, per Body Positive's own figures, and nearly two decades of New Zealand research says the same. A prescription requires that conversation to have already happened — and then requires raising, specifically, that you want it because anal sex is painful without it. For half the guys this system is nominally for, that's not an extra step. That's the wall.

Even past the wall, most doctors won't help. Under New Zealand's own prescribing guidance, liability for an adverse outcome from an unapproved medicine sits personally with the prescriber. No New Zealand datasheet lists this use for anything. That's a real, well-founded reason for a GP to say no — not just awkwardness about the topic — and it's why Fisher counts three willing doctors in the whole country.

There are two different lawful pathways, and they get muddled together. One: any GP can write a standard script for the pharmacy ampoule — a genuine pharmaceutical product, made to USP standard, the same class of thing hospitals keep in cyanide antidote kits. "Unapproved" in New Zealand only in the paperwork sense that nobody has filed to register it here. Two: personal import under section 29 of the Medicines Act, capped at six bottles per 90 days, where the doctor is vouching for an unverified consumer product from an overseas retailer — and where the script can legally name any alkyl nitrite, isopropyl included. The first carries far less risk for the doctor than the second, which is probably why it exists at all.

And even where the lawful pathway works, it doesn't match how guys actually use this. The ampoule is one measured dose for one discrete moment — which is exactly right for its prescribed purpose, and nothing like a session. One New Zealand reviewer who tried it, writing for the Burnett Foundation, rated it well against the usual bottles — smooth rush, no hangover headache — but the practical limits are obvious: one hit per vial, easy to lose in the moment, and the cost stacks fast. The only compliant product in the country simply isn't shaped for most of what people use amyl for.

What it adds up to

Is this discrimination? Here's what's documented — not asserted. The 2020 petitioners explicitly framed the reclassification as effectively criminalising gay and bisexual men. Dr Peter Saxton, a University of Auckland researcher, is on record saying Medsafe could have been more wary of discrimination in how this was handled. And the Committee's own 2019 minutes record it questioning, at the point of decision, whether the affected community even knew this was being considered. No tribunal has ruled on it. But the pattern is documented from three independent directions, and they all point the same way.

Neither country we compare ourselves to actually gets this right

The 2020 decision leaned on what other countries were doing. So it's worth being precise about what those countries actually deliver today.

Australia's law is more precise than ours. Its market doesn't exist. Despite amyl being legally pharmacist-only — no prescription — since February 2020, no company has ever registered an approved amyl product with Australia's regulator. Not one has reached a pharmacy shelf. A Sydney pharmacist told a reporter in 2024 he didn't know what poppers were. Australia's own Alcohol and Drug Foundation confirms there are still no approved products. New Zealand's awkward two-pharmacy workaround currently delivers more actual product than Australia's cleaner law does.

The UK's tolerance runs on a labelling fiction. There's no legal age limit on poppers in the UK — 18+ is voluntary retailer practice. And the product is only legal because it's sold as "not for human consumption" — room odouriser, leather cleaner — the same fiction our own sex shops used for decades. The UK government's own 2024 review says plainly that "not for inhalation" labels add to user confusion and increase the risk of accidental ingestion.

And this was never only a gay thing, even though the entire record treats it that way. Research from the UK, US and Australia documents use among heterosexual couples and women too — at consistently lower rates than among gay and bi men, but real. The whole New Zealand record — petition, submissions, joint letter, the Otago research — was argued specifically around men who have sex with men. That's an accurate reflection of how the fight happened. It also means the classification's effect on everyone else who uses the same product for the same reasons has never once been part of any public submission or government analysis.

Where this stands — and what I've done

Burnett Foundation Aotearoa and Body Positive both opposed the reclassification in 2020 — submissions made, public comment given. Since then, both have focused their public guidance on helping people navigate the pathway that exists rather than continuing to push for its reversal.

So on 3 July 2026, I sent a formal letter to the Group Manager of Medsafe and the Minister of Health. It states two positions directly: that the process behind this classification did not meet the standard of fair and reasonable administration expected of a government agency, and that the classification's practical effect discriminates against gay and bisexual men. It puts eight specific questions to the Ministry — including what became of the Committee's own undertakings, what evidence specific to amyl (as distinct from isopropyl) ever supported restricting it, and whether anyone has ever checked what six years of this policy actually did.

The letter also says what I think a defensible system looks like, so nobody has to guess: alkyl nitrites regulated as an age-restricted (R18) consumer product — not a medicine — with mandatory compound-specific labelling and honest safety information, including explicit warnings on isopropyl and n-propyl nitrite, the compounds actually tied to the documented harm. No country has achieved that yet. New Zealand could be the first to get this right, instead of the last to correct a model that has failed everywhere it's been tried.

The letter requests a substantive response within 20 working days. If that passes with silence or deflection, the matter goes to the Ombudsman, and the discrimination concern goes to the Human Rights Commission.

The clock is running. Whatever comes back — a real answer, a deflection, or nothing — you'll read about it here